AbbVie Inc.(ABBV)Stock Performance & ReturnsNYSE
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ABBV | 510.84 B | 78.98x | 10.20% | 9.80% | $3.66 | - | - | 2.41% | $291.33 | $190.75 |
950160.KQ | 1.31 T | - | - | - | - | - | - | - | $149000.00 | $11470.00 |
AMGN | 237.31 B | 26.41x | 9.50% | 22.95% | $16.62 | 91.47% | 4.90x | 2.26% | $447.03 | $280.23 |
950220.KQ | 57.50 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for AbbVie Inc. (ABBV) compared to its primary competitors (including 950160.KQ, AMGN, 950220.KQ) reveals distinct metrics. ABBV trades at a valuation premium compared to its competitors, with a P/E ratio of 79.0x versus the peer average of 26.4x (representing a 199% premium). This indicates that the market expects superior growth or commands a quality premium for ABBV. In terms of growth, ABBV's revenue growth of 10.2% lags behind the peer average of 2284.4%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 9.8% is comparable to the peer average of 11.5%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ABBV ranks #2 in P/E ratio, #2 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-21 | $287.63 | $289.00 | $282.15 | $284.80 | 4,391,916 | -1.48% |
| 2026-10-20 | $286.90 | $290.98 | $285.00 | $289.08 | 5,175,000 | +2.26% |
| 2026-10-19 | $284.23 | $287.93 | $282.59 | $282.68 | 4,171,300 | -0.96% |
| 2026-10-16 | $283.61 | $286.64 | $282.96 | $285.42 | 5,776,000 | +0.71% |
| 2026-10-15 | $288.28 | $291.40 | $282.81 | $283.40 | 7,620,300 | +0.59% |
| 2026-10-14 | $275.31 | $283.66 | $274.29 | $281.75 | 5,624,300 | +3.32% |
| 2026-10-13 | $281.56 | $281.70 | $272.03 | $272.69 | 6,408,500 | -2.40% |
| 2026-10-12 | $275.96 | $279.58 | $274.33 | $279.40 | 5,593,700 | +1.68% |
| 2026-10-09 | $269.87 | $275.91 | $268.73 | $274.78 | 4,297,400 | +0.87% |
| 2026-10-08 | $270.98 | $272.52 | $265.71 | $272.42 | 5,492,300 | +0.39% |
| 2026-10-07 | $268.40 | $274.94 | $266.89 | $271.36 | 6,077,000 | +1.75% |
| 2026-10-06 | $267.74 | $268.86 | $260.62 | $266.69 | 4,500,700 | +0.35% |
| 2026-10-05 | $261.27 | $267.34 | $260.29 | $265.76 | 7,542,000 | +1.12% |
| 2026-10-02 | $259.74 | $264.06 | $257.87 | $262.82 | 5,861,400 | +1.11% |
| 2026-10-01 | $260.51 | $262.32 | $259.00 | $259.93 | 3,889,900 | -0.63% |
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.